# Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

> **NCT03124108** · PHASE2 · COMPLETED · sponsor: **Genfit** · enrollment: 45 (actual)

## Conditions studied

- Primary Biliary Cholangitis (PBC)

## Interventions

- **DRUG:** Elafibranor 80 mg
- **DRUG:** Elafibranor 120 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03124108
- **Lead sponsor:** Genfit
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-05
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-10-31
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2019-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03124108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03124108, "Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03124108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*